Success with agentic AI won’t come from racing to adopt the flashiest tools. It will come from strategic alignment, understanding where AI can create real value, mitigating risk through thoughtful implementation, and ensuring transparency and oversight at every step.
Bispecific antibodies are already available for treating multiple myeloma. FDA approval of Regeneron Pharmaceuticals’ new drug, Lynozyfic, comes with dosing flexibility that sets it apart from others in its class.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Organon said OG-6219 did not beat a placebo in a mid-stage clinical trial whose main goal was to measure the change in pelvic pain caused by endometriosis. The twice-daily pill came from Organon’s 2021 acquisition of Forendo Pharma.
Instead of an engineered peptide to activate gut receptors to trigger metabolic effects, Syntis’s technology forms a coating in intestines that has the effect of redirecting nutrients, mimicking an effect of gastric bypass surgery. In other obesity medicine news, Protagonist Therapeutics revealed a drug candidate that puts it in competition with Novo Nordisk and Eli Lilly, among others.
Neopharmed Gentili is acquiring European rights to Orladeyo, bringing the Italy-based pharmaceutical company into rare disease. BioCryst’s Orladeyo is approved for treating patients with the rare disease hereditary angioedema.
Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Nektar Therapeutics’ biologic drug rezpegaldesleukin takes a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis.
It's a bold attempt to recalibrate global drug pricing — with U.S. patients at the center. But without clear enforcement, legal grounding, or international cooperation, its future remains very uncertain.
Draig Therapeutics’ lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is associated with mood disorders. The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing.
Gilead Sciences drug lenacapavir, brand name Yeztugo, is now approved for HIV pre-exposure prophylaxis. The twice injectable medication is hoped to improve uptake and adherence to PrEP.
Break down the silos. Take control of your provider data.
Bristol Myers Squibb’s new multibillion-dollar partnership in a hot area of cancer research overshadowed many of the announcements at the recent annual meeting of the American Society of Clinical Oncology in Chicago. We covered that news and other developments from the largest cancer conference in the world.
AstraZeneca’s R&D collaboration with CSPC Pharmaceutical Group includes an oral small molecule for immunological diseases, which would offer a dosing edge over currently available injectable medications. The agreement follows a 2024 licensing agreement that granted AstraZeneca rights to an oral CSPC drug candidate in development for a metabolic disorder.
In the past, arbitrary maintenance schedules and planned downtime were necessary expenses. Now we have the tools to think and work differently
Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry into radiopharmaceuticals via the $4.1 billion acquisition of RayzeBio last year.
The letter is an extraordinary rebuke of the Trump administration’s actions against the NIH, which include: terminating hundreds of grants funding scientific and biomedical research; firing more than 1,000 employees this year; and moving to end billions in funds to partner institutions overseas.